MA52411B1 - Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies - Google Patents
Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergiesInfo
- Publication number
- MA52411B1 MA52411B1 MA52411A MA52411A MA52411B1 MA 52411 B1 MA52411 B1 MA 52411B1 MA 52411 A MA52411 A MA 52411A MA 52411 A MA52411 A MA 52411A MA 52411 B1 MA52411 B1 MA 52411B1
- Authority
- MA
- Morocco
- Prior art keywords
- fluorine
- methyl
- deuterium
- cyclopropyl
- formula
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 title 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 6
- 229910052731 fluorine Inorganic materials 0.000 abstract 6
- 239000011737 fluorine Substances 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 4
- 229910052805 deuterium Inorganic materials 0.000 abstract 4
- 150000001408 amides Chemical class 0.000 abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 150000002825 nitriles Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 methoxy, cyclopropyl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des dérivés de quinazoline de formule (i), des compositions pharmaceutiques comprenant les composés de formule (i), et l'utilisation des composés de formule (i) dans le traitement ou la prévention d'une infection virale, d'une maladie induite par un virus, du cancer ou d'une allergie. Dans la formule (i), r1 représente un alkyle en c3-8, éventuellement substitué par un ou plusieurs substituants choisis indépendamment parmi le fluor, hydroxyle, amino, nitrile, ester, amide, alkyle en c1-3, ou alcoxy en c1-3, le carbone de r1 lié à l'amine en position 4 de la quinazoline est dans la configuration (r), r2 représente l'hydrogène, deutérium, fluor, chlore, méthyle, méthoxy, cyclopropyle, trifluorométhyle, ou amide carboxylique, chacun parmi le méthyle, méthoxy et cyclopropyle étant éventuellement substitué par un ou plusieurs substituants indépendamment choisis parmi le fluor et le nitrile, r3 représente l'hydrogène ou le deutérium, r4 représente l'hydrogène, deutérium, fluor, méthyle, ester carboxylique, amide carboxylique, nitrile, cyclopropyle, hétérocycle en c4-7, ou un groupe hétéroaryle à 5 chaînons, chacun des groupes méthyle, cyclopropyle, hétérocycle en c4-7 et hétéroaryle à 5 chaînons étant éventuellement substitué par un ou plusieurs substituants indépendamment choisis parmi le fluor, hydroxyle, ou méthyle, r5 représente un atome d'hydrogène, de deutérium, de fluor, de chlore, de méthyle ou de méthoxy, à condition qu'au moins l'un de r2, r3, r4 et r5 ne représentent pas de l'hydrogène.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18159583 | 2018-03-01 | ||
| PCT/EP2019/054941 WO2019166532A1 (fr) | 2018-03-01 | 2019-02-28 | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52411A MA52411A (fr) | 2021-01-06 |
| MA52411B1 true MA52411B1 (fr) | 2022-12-30 |
Family
ID=61557126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52411A MA52411B1 (fr) | 2018-03-01 | 2019-02-28 | Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11597704B2 (fr) |
| EP (2) | EP3759083B1 (fr) |
| JP (1) | JP2021514981A (fr) |
| KR (1) | KR20200128394A (fr) |
| CN (1) | CN111868040A (fr) |
| AR (1) | AR114420A1 (fr) |
| AU (1) | AU2019226342B2 (fr) |
| BR (1) | BR112020017702A2 (fr) |
| CA (1) | CA3091076A1 (fr) |
| CL (3) | CL2020002253A1 (fr) |
| CY (1) | CY1125489T1 (fr) |
| DK (1) | DK3759083T3 (fr) |
| EA (1) | EA202092052A1 (fr) |
| ES (1) | ES2923579T3 (fr) |
| HR (1) | HRP20220781T1 (fr) |
| HU (1) | HUE059149T2 (fr) |
| IL (2) | IL305388A (fr) |
| JO (2) | JOP20200208B1 (fr) |
| LT (1) | LT3759083T (fr) |
| MA (1) | MA52411B1 (fr) |
| MD (1) | MD3759083T2 (fr) |
| MX (2) | MX2020009071A (fr) |
| PH (1) | PH12020551345A1 (fr) |
| PL (1) | PL3759083T3 (fr) |
| PT (1) | PT3759083T (fr) |
| RS (1) | RS63401B1 (fr) |
| SG (1) | SG11202008293YA (fr) |
| SI (1) | SI3759083T1 (fr) |
| SM (1) | SMT202200315T1 (fr) |
| TW (2) | TW202415645A (fr) |
| UA (1) | UA127590C2 (fr) |
| WO (1) | WO2019166532A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7336191B2 (ja) | 2015-08-07 | 2023-08-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法 |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| TW202415645A (zh) * | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| KR102903509B1 (ko) * | 2019-01-14 | 2025-12-22 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린 |
| US20220241402A1 (en) * | 2019-06-18 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
| EP4019517A4 (fr) | 2019-08-19 | 2023-01-18 | Shanghai Zhimeng Biopharma, Inc. | Composés de 2-aminopyrimidine, compositions pharmaceutiques et utilisations associées |
| CN114555565B (zh) * | 2019-12-13 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| MX2022008286A (es) | 2020-01-02 | 2022-08-08 | Jiangsu Hengrui Medicine Co | Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma. |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3012964A (en) | 1958-06-24 | 1961-12-12 | Universal Oil Prod Co | Hydrocarbon oil composition |
| US3022077A (en) | 1958-09-15 | 1962-02-20 | Doonan William | Arrowhead construction |
| JP2610889B2 (ja) | 1987-09-03 | 1997-05-14 | 日本臓器製薬株式会社 | 新規架橋アデニン誘導体 |
| TW552261B (en) | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
| BR9711970A (pt) | 1996-08-28 | 1999-08-24 | Pfizer | Derivados 6,5-substitu¡do-heterobic¡clicos |
| CN1083841C (zh) | 1996-10-04 | 2002-05-01 | 杏林制药株式会社 | 吡唑并吡啶基哒嗪酮衍生物及其制备方法 |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| US6329381B1 (en) | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| JP4315300B2 (ja) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | 新規なキナゾリン誘導体 |
| DE69917469T2 (de) | 1998-08-27 | 2005-05-12 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidin derivate |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| CA2323008C (fr) | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Composes pharmaceutiques actifs |
| WO2002088079A2 (fr) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Inhibiteurs doubles de pde 7 et pde 4 |
| AU2002364211A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
| JP4768263B2 (ja) | 2002-09-27 | 2011-09-07 | 大日本住友製薬株式会社 | 新規アデニン化合物及びその用途 |
| US8455458B2 (en) | 2002-10-16 | 2013-06-04 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage |
| AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
| JP2007504232A (ja) | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与 |
| CN1938307B (zh) | 2004-03-26 | 2010-06-16 | 大日本住友制药株式会社 | 9-取代的8-氧代腺嘌呤 |
| US20070225303A1 (en) | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
| WO2007084413A2 (fr) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Procedes de traitement de l’hepatite c |
| JP5031564B2 (ja) | 2004-08-10 | 2012-09-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体 |
| WO2006050843A1 (fr) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Composes aminoquinazolines |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| CN101203519A (zh) | 2005-05-04 | 2008-06-18 | 辉瑞有限公司 | 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物 |
| EP1877411B9 (fr) | 2005-05-05 | 2012-08-29 | Ardea Biosciences, Inc. | Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih |
| AR054122A1 (es) | 2005-05-12 | 2007-06-06 | Tibotec Pharm Ltd | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas |
| US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| ES2612890T3 (es) | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| US20070099941A1 (en) | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| EP1970373A1 (fr) | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Compose heterocyclique alicyclique |
| BRPI0707945A2 (pt) | 2006-02-17 | 2011-05-17 | Pfizer Ltd | derivados de 3-deazapurina como modulares de tlr7 |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008009077A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés quinazoline 4,6-disubstitués et 2,4,6-trisubstitués et compositions pharmaceutiques utiles pour traiter des infections virales |
| ES2571028T3 (es) | 2006-12-07 | 2016-05-23 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso |
| CA2672250C (fr) | 2006-12-20 | 2013-04-30 | Ian Stansfield | Indoles antiviraux |
| DK2510946T3 (en) | 2007-02-07 | 2015-11-02 | Univ California | Conjugates of synthetic fluorescent agonists and their applications |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| ES2457316T3 (es) | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| EP2138497A4 (fr) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Nouveau composé d'adénine |
| US9150556B2 (en) | 2007-05-22 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Benzimidazolone chymase inhibitors |
| EP2170888B1 (fr) | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Dérivés de purine et leur utilisation comme modulateurs du récepteur de type toll-7 |
| EA201000201A1 (ru) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций |
| US8440681B2 (en) | 2007-08-28 | 2013-05-14 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| WO2009030998A1 (fr) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Composés pyrimidine utilisés comme agonistes du récepteur de type toll (tlr) |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| CN101910177B (zh) | 2007-12-24 | 2013-08-28 | 泰博特克药品公司 | 作为丙型肝炎病毒抑制剂的大环吲哚 |
| MX2010008697A (es) | 2008-02-07 | 2010-12-07 | Univ California | Tratamiento de enfermedades de la vejiga con un activador de tlr7. |
| EP2271345B1 (fr) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase hcv ns3 |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| WO2010014913A1 (fr) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Formulations d'agoniste des récepteurs de type toll et leur utilisation |
| JP5913093B2 (ja) | 2009-05-21 | 2016-04-27 | アストラゼネカ アクチボラグ | 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用 |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| ES2644286T3 (es) | 2009-10-22 | 2017-11-28 | Gilead Sciences, Inc. | Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas |
| KR101094446B1 (ko) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| BR112013007678A2 (pt) | 2010-10-01 | 2017-07-04 | Ventirx Pharmaceuticals Inc | método para tratamento de doenças alérgicas |
| WO2012066335A1 (fr) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Composés phénol en tant qu'agonistes du récepteur 7 de type toll |
| WO2012067269A1 (fr) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies |
| SI3590928T1 (sl) * | 2011-04-08 | 2021-10-29 | Janssen Sciences Ireland Unlimited Co | Derivati pirimidina za zdravljenje virusnih okužb |
| US8916575B2 (en) * | 2011-05-18 | 2014-12-23 | Janssen R&D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| EA036645B1 (ru) | 2011-11-09 | 2020-12-03 | Янссен Сайенсиз Айрлэнд Юси | Производные пурина для лечения вирусных инфекций |
| EP2812331B1 (fr) | 2012-02-08 | 2019-01-02 | Janssen Sciences Ireland Unlimited Company | Dérivés de la pipéridino-pyrimidine pour le traitement des infections virales |
| CN106977495B (zh) | 2012-04-24 | 2020-08-04 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
| MY167797A (en) | 2012-07-13 | 2018-09-26 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
| CN104781239B (zh) | 2012-08-10 | 2019-03-01 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物 |
| CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
| EP2712866A1 (fr) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | Dérivés de 1,2,4-triazine pour le traitement d'infections virales |
| CA2882786C (fr) | 2012-10-05 | 2020-10-20 | Janssen Sciences Ireland Uc | Derives d'acylaminopyrimidine pour le traitement d'infections virales et d'autres maladies. |
| EP2906563B1 (fr) | 2012-10-10 | 2018-02-28 | Janssen Sciences Ireland UC | Dérivés de pyrrolo[3,2-d] pyrimidine pour le traitement d'infections virales et d'autres maladies |
| AU2013346793B2 (en) | 2012-11-16 | 2018-03-08 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
| HRP20170654T1 (hr) | 2013-03-29 | 2017-06-30 | Janssen Sciences Ireland Uc | Makrociklički deaza-purinoni za liječenje virusnih infekcija |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| WO2014187932A1 (fr) | 2013-05-24 | 2014-11-27 | Janssen R&D Ireland | Dérivés de pyridone pour le traitement d'infections virales et d'autres maladies |
| CA2913028C (fr) * | 2013-06-27 | 2022-03-08 | Janssen Sciences Ireland Uc | Derives de pyrrolo[3,2-d]pyrimidine pour le traitement des infections virales et autres maladies |
| JP6401788B2 (ja) | 2013-07-30 | 2018-10-10 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体 |
| US9701661B2 (en) | 2014-07-11 | 2017-07-11 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
| CU20180011A7 (es) * | 2015-03-04 | 2018-06-05 | Gilead Sciences Inc | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll |
| AR107633A1 (es) | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
| MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
| WO2018002319A1 (fr) * | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Uc | Dihydropyranopyrimidines pour le traitement d'infections virales |
| PL3507276T3 (pl) * | 2016-09-02 | 2022-02-21 | Gilead Sciences, Inc. | Związki modulatory receptorów toll-podobnych |
| TW202415645A (zh) * | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
-
2019
- 2019-02-26 TW TW112147878A patent/TW202415645A/zh unknown
- 2019-02-26 TW TW108106429A patent/TW201945003A/zh unknown
- 2019-02-28 EA EA202092052A patent/EA202092052A1/ru unknown
- 2019-02-28 LT LTEPPCT/EP2019/054941T patent/LT3759083T/lt unknown
- 2019-02-28 AU AU2019226342A patent/AU2019226342B2/en not_active Expired - Fee Related
- 2019-02-28 CA CA3091076A patent/CA3091076A1/fr active Pending
- 2019-02-28 KR KR1020207024889A patent/KR20200128394A/ko not_active Withdrawn
- 2019-02-28 IL IL305388A patent/IL305388A/en unknown
- 2019-02-28 HR HRP20220781TT patent/HRP20220781T1/hr unknown
- 2019-02-28 US US16/977,043 patent/US11597704B2/en active Active
- 2019-02-28 ES ES19708817T patent/ES2923579T3/es active Active
- 2019-02-28 SM SM20220315T patent/SMT202200315T1/it unknown
- 2019-02-28 WO PCT/EP2019/054941 patent/WO2019166532A1/fr not_active Ceased
- 2019-02-28 HU HUE19708817A patent/HUE059149T2/hu unknown
- 2019-02-28 MX MX2020009071A patent/MX2020009071A/es unknown
- 2019-02-28 EP EP19708817.2A patent/EP3759083B1/fr active Active
- 2019-02-28 PL PL19708817.2T patent/PL3759083T3/pl unknown
- 2019-02-28 MD MDE20210025T patent/MD3759083T2/ro unknown
- 2019-02-28 BR BR112020017702-4A patent/BR112020017702A2/pt unknown
- 2019-02-28 PT PT197088172T patent/PT3759083T/pt unknown
- 2019-02-28 SG SG11202008293YA patent/SG11202008293YA/en unknown
- 2019-02-28 IL IL276952A patent/IL276952B2/en unknown
- 2019-02-28 RS RS20220684A patent/RS63401B1/sr unknown
- 2019-02-28 JP JP2020544896A patent/JP2021514981A/ja not_active Ceased
- 2019-02-28 CN CN201980016340.4A patent/CN111868040A/zh active Pending
- 2019-02-28 UA UAA202006229A patent/UA127590C2/uk unknown
- 2019-02-28 SI SI201930268T patent/SI3759083T1/sl unknown
- 2019-02-28 EP EP22170830.8A patent/EP4059924A1/fr not_active Withdrawn
- 2019-02-28 MA MA52411A patent/MA52411B1/fr unknown
- 2019-02-28 DK DK19708817.2T patent/DK3759083T3/da active
- 2019-02-28 AR ARP190100506A patent/AR114420A1/es not_active Application Discontinuation
-
2020
- 2020-08-27 PH PH12020551345A patent/PH12020551345A1/en unknown
- 2020-08-30 JO JOJO/P/2020/0208A patent/JOP20200208B1/ar active
- 2020-08-31 MX MX2023001803A patent/MX2023001803A/es unknown
- 2020-08-31 CL CL2020002253A patent/CL2020002253A1/es unknown
-
2021
- 2021-06-30 CL CL2021001753A patent/CL2021001753A1/es unknown
-
2022
- 2022-01-18 CL CL2022000125A patent/CL2022000125A1/es unknown
- 2022-07-27 CY CY20221100514T patent/CY1125489T1/el unknown
-
2023
- 2023-01-24 US US18/159,026 patent/US20230278964A1/en not_active Abandoned
- 2023-09-05 JO JOJO/P/2023/0207A patent/JOP20230207A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52411B1 (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies | |
| RU2378263C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| MA58170B1 (fr) | Dérivés carboxy avec des proprietes anti-inflammatoires | |
| MA44021B1 (fr) | Composés antitumoraux | |
| MA27764A1 (fr) | Acides carboxyliques alpha-substitués servant de modulateurs de PPAR | |
| MA42795A (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| JP2019512485A5 (fr) | ||
| ME00376B (me) | DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA52795B1 (fr) | Dérivés de carbamoylpyridone polycycliques pour le traitement du vih | |
| EA202092159A1 (ru) | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение | |
| EA202193223A1 (ru) | Другие гетероароматические соединения, действующие против рсв | |
| FR3037953B1 (fr) | Procede de synthese de molecules portant une fonction oxyde de nitrile | |
| MA41885B1 (fr) | Mélange d'additifs | |
| TNSN07043A1 (fr) | Oxazolidinones contenant des oxindoles, servant d'agents antibacteriens | |
| CA2531484A1 (fr) | Nouveaux bioisosteres d'actinonine | |
| ZA202405279B (en) | Heteroaryl derivative and use thereof | |
| MA56324B1 (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| EA201070040A1 (ru) | Новые соединения, соединения, которые влияют на клеточные везикулярные системы, фармацевтические композиции и их применение | |
| FR3058640B1 (fr) | Composes pour leur utilisation dans le traitement de la grippe | |
| FR3092114B1 (fr) | Nouveaux derives de purine et medicaments les comprenant | |
| NZ768393B2 (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof | |
| MA57420B1 (fr) | Composés anticancéreux | |
| NZ807753A (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof |